TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged 40 years or older~* Patients with moderate to severe COPD according to the GOLD Guidelines (2006)~* Patients who have smoking history of at least 10 pack years~* Patients with a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) equal or greater than 30% of the predicted normal value and less than 80% of the predicted normal value, and post-bronchodilator FEV1/FVC less than 0.7 at visit 2~* Written informed consent by the patient prior to initiation of any study-related procedure~Exclusion Criteria:~* Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to visit 1 or during the screening period (up to visit 3).~* Patients who have had a respiratory tract infection within 6 weeks prior to visit 1 or during the screening period (up to visit 3).~* Patients with a history of asthma indicated by (but not limited to):~Blood eosinophil count \> 400/mm3, onset of symptoms prior to age 40 years.~* Patients with a history of long QT syndrome or whose QTc measured at visit 1 is prolonged (more than 440 ms for males or more than 460 ms for females).~* Patients with a history of untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.~* Patients who, in the judgment of the investigator have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to) unstable ischemic heart disease, left ventricular failure, long term prednisone therapy, history of myocardial infarction, arrhythmia, narrow-angle glaucoma, symptomatic prostatic hyperplasia, bladder-neck obstruction or moderate to severe renal impairment that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.~* History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 100 µg (Type: EXPERIMENTAL): None
- NVA237 200 µg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent~* Minimum Wexner Bowel incontinence score of 12 AND at least weekly (score of 3 or higher) leakage of solid and/or liquid type stool, with no greater than 50% of subjects with daily (score 4) of uncontrolled gas.~* Patients colon surveillance must be in compliance with American Cancer Society colon screening guidelines. If patient is out of compliance, they may be scheduled for Colonoscopy.~* Patient comprehends study meaning \& is capable of carrying out study duties~* Fluent in English~Exclusion Criteria:~* American Society of Anesthesiologist (ASA) score of 4 or higher~* Spinal cord injury or other major neurological diagnosis~* Known immune deficiency state~* Significant cardiac arrhythmia~* Pregnant or Breastfeeding~* Inflammatory bowel disease~* Requirement of medication delivered by suppository~* Active perianal abscess or fistula~* Present rectal prolapse~* Third degree hemorrhoids~* Anal stricture~* History or rectal spasm~* Rectal surgery in past 6 months~* Unresolved Anismus~* Fecal impaction with overflow diarrhea~* Ileo-anal pouch~* Rectocele requiring surgery~* Allergy to silicone or one of its components~* Significant medical condition which interferes with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment for Children With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 2 and 16 years and referral to our out patient clinic with either constipation or fecal incontinence.~* Patients must fulfill the Rome III criteria of constipation, which mean they must have at least 2 of the following characteristics: fewer than 3 bowel movements weekly, more than 1 episode of fecal incontinence weekly, large stools in the rectum by digital rectal examination or palpable on abdominal examination, occasional passing of large stools, display of retentive posturing and withholding behavior, and painful defecation.~Exclusion Criteria:~* Children with known organic causes of constipation, including Hirsprung disease, spinal and anal congenital abnormalities, previous surgery on the colon, inflammatory bowel disease, allergy and metabolic or endocrine diseases.~* Children receiving drugs known to affect bowel function during a 2 month period before initiation.~* The healthy control group consists of children with no history of constipation (Rome III), urinary incontinence, urinary tract infections, fecal incontinence, laxative use or any other disease affecting the digestive system.~* Children receiving medications known to affect bowel function are excluded from the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Active maintenance treatment (Type: ACTIVE_COMPARATOR): None
- Placebo maintenance treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preserved left ventricular function (LVEF \> 50%)~* Normal preoperative S-creatinine~Exclusion Criteria:~* Contraindications to radiocontrast~* Cardiac transplantation och dissection

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy (surgery and/or radiotherapy).~* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive breast cancer~* Patient has HER2-negative breast cancer~* Patient has adequate bone marrow and organ function~Exclusion Criteria:~* Patient who received any CDK4/6 inhibitor.~* Patient has a known hypersensitivity to any of the excipients of LEE011 or letrozole~* Patients with inflammatory breast cancer.~* Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer~* Patient is currently using other anti-cancer therapy~* Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.~* Patient who has received radiotherapy ≤ 4 weeks~* Patient has a concurrent malignancy or malignancy within 3 years~* Patient has metastases to the central nervous system (CNS).~* Patient has a known history of HIV infection~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEE011 +Letrozole (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
- LEE011 + Tamoxifen (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
- LEE011 + Fulvestrant (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total Knee arthroplasty American Society of Anesthesiologist score of 1-3 Age 18-85 Elective total knee arthroplasty under spinal anesthetic.~Exclusion Criteria:~* Contraindication to Dexmedetomidine. (second or third degree heart block, renal or hepatic dysfunction) Contraindication to Spinal Anesthetic Pain being treated by opioids prior to operation Contraindication to premedication Previous total knee arthroplasty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Dexmedetomidine arm (Type: EXPERIMENTAL): Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA.
- Saline Placebo (Type: PLACEBO_COMPARATOR): Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mortality Reduction After Oral Azithromycin: Mortality Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Communities~* The community location in target district.~* The community leader consents to participation in the trial~* The community's estimated population is between 200-2,000 people.~* The community is not in an urban area.~Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.~Exclusion Criteria:~Individuals~- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 60 Months
- Healthy Volunteers: t

Study Arms:
- Biannual mass oral azithromycin (Type: ACTIVE_COMPARATOR): Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.~In Niger during year 3, all communities will be offered azithroymcin.
- Biannual mass oral placebo (Type: PLACEBO_COMPARATOR): Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~In Niger during year 3, all communities will be offered azithroymcin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensified Post Remission Therapy Containing PEG-Asparaginase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with previously untreated ALL subtypes L1 and L2.~* Patients with de novo Philadelphia (Ph)+ ALL (i.e. excluding those that are after blastic of CML) are eligible. However they will be referred to allogeneic hematopoietic stem cell transplantation and will continue on the study until they are ready to undergo the transplantation. At that time they will discontinue the study. Patients who are unable to undergo allogeneic transplantation will continue on the study.~* Presence of 25% or more of lymphoblasts in the bone marrow by FAB criteria, confirmed by TdT positivity or by flow cytometry with standard ALL markers.~* Patients may have received prior steroids.~* Age: 18 - 55 years~* Signed Informed Consent~Exclusion Criteria:~* Patients with Burkitt's ALL (L3 subtype) or CML lymphoblastic crisis are not eligible (including CML patients who present with ALL blastic crisis).~* Psychological or emotional disorders which will make a valid informed consent impossible.~* Bilirubin \>1.5 mg/dl, creatinine \> 2.5 mg/dl~* Symptomatic congestive heart failure or unstable angina~* Pregnant or lactating females~* Known HIV positive status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Intensified Post-Remission: MTX/LV/PEG-Asparaginase (Type: EXPERIMENTAL): Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 \& 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Informed consent~* Otherwise healthy outpatient with mountain cedar allergy~* Male or eligible female Females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control~* Age 12 years or older at Visit 2~* Diagnosis of seasonal allergic rhinitis (SAR) to mountain cedar~* Adequate exposure to mountain cedar pollen~* Ability to comply with study procedures~* Literate~Exclusion criteria:~* Significant concomitant medical conditions~* Use of intranasal corticosteroids within four weeks prior to Visit 1; use of inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less) within eight weeks prior to Visit 1.~* Use of other allergy medications within specific timeframes relative to Visit 1~* Use of other medications that may affect allergic rhinitis or its symptoms~* Use of immunosuppressive medications eight weeks prior to screening and during the study~* Immunotherapy patients who are not stable on current dose~* Use of any medications that significantly alters the pharmacokinetics of fluticasone furoate or fexofenadine~* Allergy/Intolerance to corticosteroids, antihistamines, or any excipients in the two products~* Use of contact lenses~* Recent clinical trial/experimental medication experience within 30 days of Visit 1~* Subject previously failed the 21-day screen period or failed to complete the treatment period~* Positive or inconclusive pregnancy test or female who is breastfeeding~* Employee or relative affiliation with investigational site~* Current tobacco use~* Active chickenpox or measles or exposure in the last 3 weeks

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Cortiment® in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged ≥ 18 years~* Outpatients~* Patients who have been prescribed Cortiment® for the treatment of mild to moderate active ulcerative colitis within a 5 days' time window prior to being included in the study~* Patients who have received adequate information regarding this non-interventional study and are able to understand and voluntarily sign the Informed Consent~Exclusion Criteria:~* Patients with severe active / fulminant ulcerative colitis~* Patients treated with antibiotics or corticosteroids for the current flare. Use of Antibiotics for other conditions non-related to the gastrointestinal tract, either before enrolment or during the observational period is permitted.~* History of total / sub-total colectomy~* Hypersensitivity to the active substance, lecithin (derived soya oil, peanut oil) or to any of the excipients~* Patients enrolled and involved in an interventional study~* Patients whom investigators consider inappropriate to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cortiment® (Type: None): Treatment according to routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current healthy smoker as judged by the Principal Investigator(s) or designee(s)~* Minimum age: 30 years old~* Have smoked for the last 10 years~* Have smoked more than 10 non menthol CC/day on average (no brand restriction) over the past year~Exclusion Criteria:~* Clinically relevant medical conditions that in the opinion of the investigators would jeopardize the safety of the participant.~* Subject who has (FEV1/FVC) \< 0.7 and FEV1 \< 80% predicted value at post-bronchodilator spirometry~* Subject with asthma condition (post-bronchodilator FEV1/FVC \< 0.75 and reversibility in FEV1 ≥ 12% and \> 200 mL from pre- to post-bronchodilator values)~* Subject who took or is taking concomitant medication which may have an impact on the smoker's heath profile~* Female subject is pregnant or breast feeding.~* Female subject who does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- THS 2.2 (Type: EXPERIMENTAL): Ad libitum use of THS 2.2
- CC (Type: ACTIVE_COMPARATOR): Ad libitum use of CC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete